Citius Oncology (CTOR) Shares Outstanding (2022 - 2026)
Citius Oncology (CTOR) posted quarterly Shares Outstanding (Entity) of $93.0 million for Q1 2026, up 29.95% year-over-year from $71.6 million in Q1 2025, and up 9.65% quarter-over-quarter from $84.8 million in Q4 2025.
Citius Oncology (CTOR) Shares Outstanding (2022 - 2026) Analysis & Trends
Citius Oncology (CTOR) has reported Shares Outstanding (Entity) for 5 consecutive years, with $93.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 29.95% year-over-year to $93.0 million; the TTM figure through Mar 2026 stood at $93.0 million (up 29.95% YoY), while the FY2025 annual figure was $83.5 million, up 16.72% from the prior year.
- Shares Outstanding (Entity) improved to $93.0 million in Q1 2026 per CTOR's latest filing, from $84.8 million in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $93.0 million in Q1 2026 and bottomed at $1.9 million in Q4 2022.
- Historically, Shares Outstanding (Entity) has averaged $46.1 million across 5 years, with a median of $69.5 million in 2023.
- Annual changes were most pronounced in 2023 — Shares Outstanding (Entity) soared 3518.38% — and 2024, when it plunged 34.67%.
- Citius Oncology's Shares Outstanding (Entity) stood at $1.9 million in 2022, then jumped by 3518.38% to $67.5 million in 2023, then increased by 6.0% to $71.6 million in 2024, then climbed by 18.51% to $84.8 million in 2025, then advanced by 9.65% to $93.0 million in 2026.
- Business Quant data shows CTOR's Shares Outstanding (Entity) at $93.0 million in Q1 2026, $84.8 million in Q4 2025, and $83.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.65 Bn | 42.68 Bn | - | 4.44 Bn |
| 2 | Teva Pharmaceutical Industries | 43.09 Bn | 39.44 Bn | 2.15 Bn | 1.17 Bn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | 417.60 Mn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 1.58 Bn |
| 5 | United Therapeutics | 22.11 Bn | 19.45 Bn | 683.80 Mn | 42.60 Mn |
| 6 | Viatris | 18.77 Bn | 17.88 Bn | 1.46 Bn | 1.16 Bn |
| 7 | Neurocrine Biosciences | 15.62 Bn | 15.23 Bn | 935.80 Mn | 101.00 Mn |
| 8 | Elanco Animal Health | 12.07 Bn | 11.54 Bn | 798.00 Mn | 499.50 Mn |
| 9 | Dr Reddys Laboratories | 10.09 Bn | 9.93 Bn | - | 832.44 Mn |
| 10 | Citius Oncology | 80.17 Mn | 80.17 Mn | 1.00 Mn | 107.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 100.03 Mn |
| Dec 31, 2025 | 87.46 Mn |
| Sep 30, 2025 | 73.27 Mn |
| Jun 30, 2025 | 71.55 Mn |
| Mar 31, 2025 | 71.55 Mn |
| Dec 31, 2024 | 71.55 Mn |
| Sep 30, 2024 | 68.05 Mn |
| Jun 30, 2024 | 4.31 Mn |
| Mar 31, 2024 | 4.74 Mn |
| Dec 31, 2023 | 67.50 Mn |
| Sep 30, 2023 | 6.60 Mn |
| Jun 30, 2023 | 6.60 Mn |
| Mar 31, 2023 | 6.60 Mn |
| Dec 31, 2022 | 1.87 Mn |